Compugen Reports Third Quarter 2022 Results

New encouraging preliminary clinical data, presented at SITC 2022, showing anti-tumor activity supported by potent immune activation in the tumor...

Related Keywords

Israel ,Tel Aviv ,Yvonne Naughton ,Corporate Communications Compugen Ltd ,Stock Exchange ,Compugen ,Nasdaq ,Exchange Commission ,Astrazeneca ,Securities Exchange ,Prnewswire Compugen Ltd ,Anat Cohen Dayag ,Chief Executive Officer ,South San Francisco ,Securities Act ,Securities Exchange Act ,Private Securities Litigation Reform Act ,Annual Report ,Investor Relations ,Corporate Communications Compugen ,Months Ended ,Compugen Ltd ,